GeneReach Biotechnology (4171) — Financial Flexibility Index
GeneReach Biotechnology (4171) has a Financial Flexibility Index of 0.05x as of June 2026. Free cash flow of NT$14.41 Million (operating CF NT$6.28 Million minus capex NT$8.13 Million) represents 0% of total liabilities (NT$276.64 Million). Check GeneReach Biotechnology investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GeneReach Biotechnology Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for GeneReach Biotechnology across 9 annual periods. For the full cash flow conversion analysis, see GeneReach Biotechnology (4171) cash flow conversion.
Annual Financial Flexibility Index for GeneReach Biotechnology (2017–2025)
Year-by-year free cash flow to debt coverage for GeneReach Biotechnology. Explore 4171 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.01x | NT$-1.88 Million | NT$-13.52 Million | NT$284.34 Million | ▲ +84.7% |
| 2024 | -0.04x | NT$-14.76 Million | NT$-23.22 Million | NT$341.00 Million | ▼ -20.0% |
| 2023 | -0.04x | NT$-11.32 Million | NT$-38.67 Million | NT$313.71 Million | ▼ -104.7% |
| 2022 | 0.78x | NT$402.54 Million | NT$357.63 Million | NT$519.23 Million | ▲ +26.7% |
| 2021 | 0.61x | NT$364.78 Million | NT$348.99 Million | NT$596.35 Million | ▼ -0.2% |
| 2020 | 0.61x | NT$234.69 Million | NT$169.82 Million | NT$382.75 Million | ▲ +4297.5% |
| 2019 | 0.01x | NT$2.34 Million | NT$-11.19 Million | NT$167.82 Million | ▼ -33.7% |
| 2018 | 0.02x | NT$8.05 Million | NT$5.74 Million | NT$382.68 Million | ▲ +225.0% |
| 2017 | -0.02x | NT$-5.93 Million | NT$-6.83 Million | NT$352.21 Million | — |